Therapeutic Drug Monitoring (TDM)

Why Blood Levels Matter

For most medications, prescribers infer whether a drug is working by observing clinical outcomes — blood pressure readings, pain scores, blood glucose levels, symptom diaries. These measures are sufficient when the link between dose and effect is predictable.

But for a subset of drugs, the connection between dose and effect is highly variable between individuals. Two patients taking the same dose of the same drug can have blood levels that differ by a factor of 5 or more, due to genetic differences in drug metabolism, interactions with other medications, changes in organ function, and body composition. For drugs with narrow therapeutic windows, this variability can mean the difference between effective treatment and toxicity.

In these situations, measuring the actual drug concentration in blood provides a much more reliable guide than dose alone.

What Is Therapeutic Drug MonitoringTherapeutic Drug Monitoring

The measurement of drug concentrations in blood at specific times to optimize individual dosing. TDM is essential for drugs with narrow therapeutic indices, significant pharmacokinetic variability, or

?

Therapeutic drug monitoring (TDM) is the practice of measuring drug concentrations in blood (and occasionally other fluids) to guide dosing decisions. A blood sample is drawn at a specific time relative to the most recent dose, the drug level is measured in a laboratory, and the result is compared to an established therapeutic range — the concentration associated with the best balance of efficacyEfficacy

The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than one with lower efficacy, even if the latter is

and safety in clinical studies.

If levels are below the range, the dose may be insufficient. If levels are above the range, toxicity risk is elevated. The goal is to keep drug concentrations within the window consistently.

Peak and Trough Levels

Two time points are most commonly used for TDM blood draws:

Trough level (most common): Drawn just before the next scheduled dose, when drug concentration is at its lowest point in the dosing cycle. Trough levels reflect the minimum concentration maintained throughout the dosing interval and are used to ensure levels do not drop below the therapeutic threshold.

Peak level: Drawn at the time of maximum concentration after a dose. For oral drugs, this is typically 1–2 hours post-dose; for IV drugs, timing varies. Peak levels ensure concentrations do not rise into the toxic range.

Some drugs require both peak and trough monitoring. Aminoglycoside antibiotics (gentamicin, tobramycin) use peak levels to confirm efficacy and trough levels to minimize nephrotoxicity.

Steady-State and Timing

Accurate TDM requires that the drug has reached steady-state — the equilibrium where drug levels fluctuate predictably within a stable range between doses. Measuring levels before steady-state gives a misleadingly low result, since levels are still rising.

As a general rule, steady-state is reached after approximately four to five half-lives. For vancomycin (half-lifeHalf-Life

The time required for the plasma concentration of a drug to decrease by 50%. Half-life determines how often a medication needs to be dosed — drugs with shorter half-lives require more frequent dosing

~6 hours), this means 24–30 hours. For phenytoin (half-life ~22 hours), about 4–5 days. For lithium (half-life ~24 hours), about 5 days.

This is why TDM blood draws are scheduled for after a specified number of doses, not immediately after starting a medication.

Which Drugs Require TDM?

TDM is most valuable for drugs that combine a narrow therapeutic indexTherapeutic Index

The ratio between the toxic dose and the therapeutic dose of a drug (TD50/ED50ED50

The median effective dose — the dose of a drug that produces the desired therapeutic effect in 50% of the population. ED50 is a key measure of drug potency used in comparing medications within the sam

). A narrow therapeutic index means there is a small margin between the dose that produces the desired effect and the dose

with high inter-individual variability in drug levels. Classic examples:

Anticonvulsants: Phenytoin, valproate, carbamazepine, lamotrigine. Therapeutic ranges are well-established; levels guide dose adjustments and assess adherence.

Immunosuppressants: Tacrolimus, cyclosporine, sirolimus (used after organ transplants). The difference between rejection (too low) and toxicity (too high) is narrow; TDM is essential.

Lithium: Narrow range (0.6–1.2 mEq/L typical); toxicity can cause tremors, confusion, and kidney damage. Regular monitoring is standard care.

Digoxin: Used for heart failure and atrial fibrillation; therapeutic range 0.5–2 ng/mL; toxicity causes dangerous arrhythmias.

Vancomycin: IV antibiotic for serious gram-positive infections; TDM (now typically AUC-guided rather than simple trough) optimizes efficacy and reduces nephrotoxicity.

Aminoglycosides: Gentamicin, tobramycin — peak/trough monitoring to balance bactericidal efficacy with kidney and hearing protection.

Methotrexate (high-dose regimens): Levels monitored to guide leucovorin rescue and detect dangerous accumulation.

How Results Lead to Dose Changes

When a TDM result comes back, the pharmacist or physician interprets it in context — not just the number, but when it was drawn, whether steady-state has been reached, any recent changes to other medications, and the patient's current clinical status.

A subtherapeutic level may prompt a dose increase, or — if the patient is doing well clinically — reassurance that the lower level is sufficient for this individual. A supratherapeutic level may prompt dose reduction or temporary drug hold.

The therapeutic range is a population-derived guideline, not an absolute individual target. A patient may be well-controlled at a level below the textbook range, or may need higher levels for adequate effect. Clinical judgment accompanies every TDM result.

What TDM Cannot Tell You

TDM measures drug concentration in plasma, not at the target site. It cannot directly assess tissue levels or receptor occupancy. It does not distinguish between active drug and inactive metabolites unless both are measured separately. It captures a snapshot at one moment — not fluctuations throughout the day.

TDM is also limited when the therapeutic range itself is uncertain (many newer drugs) or when the clinical response is easier to measure directly (blood pressure, blood glucose).

Key Takeaways

• Therapeutic drug monitoring measures blood drug concentrations to confirm doses are within the effective, safe range.
• TDM is used for drugs with narrow therapeutic windows and high inter-individual variability — including lithium, digoxin, vancomycin, phenytoin, and transplant immunosuppressants.
• Trough levels (before next dose) and peak levels (after a dose) serve different clinical purposes.
• Draws must be timed to steady-state; premature testing gives misleading results.
• TDM results guide dose adjustments but are interpreted alongside clinical findings, not in isolation.